Robopoli
Madmaxista
- Desde
- 14 Feb 2013
- Mensajes
- 3.407
- Fruta
- 2.649
Pufff menudo chicharraco... Ayer tuvo un día complicadete el jodío si bien es cierto que parece que en los 3,70€ está consolidando el suelo, no?
Install the app
How to install the app on iOS
Follow along with the video below to see how to install our site as a web app on your home screen.
Nota: This feature may not be available in some browsers.
Estás usando un navegador desactualizado. Es posible que no muestre este u otros sitios web correctamente.
Debe actualizar o usar un navegador alternativo.
Debe actualizar o usar un navegador alternativo.
Bio-tecnología 3D. Future is now
- Autor del tema Kali Yuga
- Fecha de inicio
Pufff menudo chicharraco... Ayer tuvo un día complicadete el jodío si bien es cierto que parece que en los 3,70€ está consolidando el suelo, no?
Ladrillófilo
Madmaxista
En rankia hay un estupendo hilo de farmas USA, deberíais buscarlo.
Me interesa el tema Onvo, y también el tema Geron. Investigaré a ver...
Me interesa el tema Onvo, y también el tema Geron. Investigaré a ver...
Ladrillófilo
Madmaxista
11,48$ ahora mismo... Me pregunto si a largo plazo es una buena idea...
Ladrillófilo
Madmaxista
Este tipo argumenta que la mejor idea de cortos en 2014 es ONVO. Estoy dentro amasando unas generosas pérdidas.
Summary
ONVO's promise of creating "3d bio-printed organs" for humans is a pipe dream decades away, and ONVO has neither the capital nor people necessary to succeed at such a venture.
ONVO's 3D bioprinting technology is far too slow and expensive to deliver a viable product for drug toxicity testing, the only near-term market identified by management.
ONVO's patent protection is extremely weak and does not come close to claiming all of the methods necessary to "print" human organs in the future.
ONVO scientific co-founder, Gabor Forgacs, has left his role at the company and is pursuing more viable opportunities (synthetic leather & meat) with notable venture capital backers.
ONVO executives are cashing out: the top three (Keith Murphy, Barry Michaels and Sharon Presnell) have sold ~$7 million worth of ONVO stock and pay themselves nearly $1 million annually.
[Editor's Note: Some facts have been corrected in this article after we were contacted by Organovo's management]
I am writing this solely to demonstrate high quality trade ideas for my investment firm, Valkyrie Capital. In doing so, I am putting my personal fruta (and that of my firm) on the line. I am not a serial short seller and ONVO had originally been brought to me as a long idea, but after some research, it has become my top short idea for 2014. While I am short, I am not looking to deliberately "short and distort" either: my position is based on detailed research, my own deductions and an expectation that Organovo's share price will decline significantly before December 2014. It's also worth noting I do not post frequently and my last post recommended long positions in Two Harbors (TWO) LEAPs and levered Annaly Capital (NLY) preferred stock on December 16th, which are both up more than 50% and 18% - 25%, respectively.
Tienes que estar registrado para ver este contenido
Summary
ONVO's promise of creating "3d bio-printed organs" for humans is a pipe dream decades away, and ONVO has neither the capital nor people necessary to succeed at such a venture.
ONVO's 3D bioprinting technology is far too slow and expensive to deliver a viable product for drug toxicity testing, the only near-term market identified by management.
ONVO's patent protection is extremely weak and does not come close to claiming all of the methods necessary to "print" human organs in the future.
ONVO scientific co-founder, Gabor Forgacs, has left his role at the company and is pursuing more viable opportunities (synthetic leather & meat) with notable venture capital backers.
ONVO executives are cashing out: the top three (Keith Murphy, Barry Michaels and Sharon Presnell) have sold ~$7 million worth of ONVO stock and pay themselves nearly $1 million annually.
[Editor's Note: Some facts have been corrected in this article after we were contacted by Organovo's management]
I am writing this solely to demonstrate high quality trade ideas for my investment firm, Valkyrie Capital. In doing so, I am putting my personal fruta (and that of my firm) on the line. I am not a serial short seller and ONVO had originally been brought to me as a long idea, but after some research, it has become my top short idea for 2014. While I am short, I am not looking to deliberately "short and distort" either: my position is based on detailed research, my own deductions and an expectation that Organovo's share price will decline significantly before December 2014. It's also worth noting I do not post frequently and my last post recommended long positions in Two Harbors (TWO) LEAPs and levered Annaly Capital (NLY) preferred stock on December 16th, which are both up more than 50% and 18% - 25%, respectively.
Robopoli
Madmaxista
- Desde
- 14 Feb 2013
- Mensajes
- 3.407
- Fruta
- 2.649
Este tipo argumenta que la mejor idea de cortos en 2014 es ONVO. Estoy dentro amasando unas generosas pérdidas.
Tienes que estar registrado para ver este contenido
Summary
ONVO's promise of creating "3d bio-printed organs" for humans is a pipe dream decades away, and ONVO has neither the capital nor people necessary to succeed at such a venture.
ONVO's 3D bioprinting technology is far too slow and expensive to deliver a viable product for drug toxicity testing, the only near-term market identified by management.
ONVO's patent protection is extremely weak and does not come close to claiming all of the methods necessary to "print" human organs in the future.
ONVO scientific co-founder, Gabor Forgacs, has left his role at the company and is pursuing more viable opportunities (synthetic leather & meat) with notable venture capital backers.
ONVO executives are cashing out: the top three (Keith Murphy, Barry Michaels and Sharon Presnell) have sold ~$7 million worth of ONVO stock and pay themselves nearly $1 million annually.
[Editor's Note: Some facts have been corrected in this article after we were contacted by Organovo's management]
I am writing this solely to demonstrate high quality trade ideas for my investment firm, Valkyrie Capital. In doing so, I am putting my personal fruta (and that of my firm) on the line. I am not a serial short seller and ONVO had originally been brought to me as a long idea, but after some research, it has become my top short idea for 2014. While I am short, I am not looking to deliberately "short and distort" either: my position is based on detailed research, my own deductions and an expectation that Organovo's share price will decline significantly before December 2014. It's also worth noting I do not post frequently and my last post recommended long positions in Two Harbors (TWO) LEAPs and levered Annaly Capital (NLY) preferred stock on December 16th, which are both up more than 50% and 18% - 25%, respectively.
Yo me salí sacando algo de plusvis pera nada superestelar al final (un 10% o algo así).
Cada vez tengo más claro que con este tipo de valores lo mejor no es el buy & hold de toda la vida. Por eso pedía arriba alguna plantilla de GAD/AIM. Para hacer un poco de backtesting y ver si se puede optimizar un poco el tema con tecnológicas, biotech y similares.
todoayen
Madmaxista
- Desde
- 17 Sep 2009
- Mensajes
- 23.007
- Fruta
- 40.421
"Cada vez tengo más claro que con este tipo de valores lo mejor no es el buy & hold de toda la vida. Por eso pedía arriba alguna plantilla de GAD/AIM. Para hacer un poco de backtesting y ver si se puede optimizar un poco el tema con tecnológicas, biotech y similares."
¿Veis como los mercados somos todos y en la bolsa entra cualquiera?
¿Quién no tiene por algún cajón una plantilla de GAD/AIM y mientras está defecando se entretiene haciendo un poco de backtesting?
¿Veis como los mercados somos todos y en la bolsa entra cualquiera?
¿Quién no tiene por algún cajón una plantilla de GAD/AIM y mientras está defecando se entretiene haciendo un poco de backtesting?
SPK
Madmaxista
- Desde
- 17 Oct 2013
- Mensajes
- 53
- Fruta
- 57
Este tipo argumenta que la mejor idea de cortos en 2014 es ONVO. Estoy dentro amasando unas generosas pérdidas.
Tienes que estar registrado para ver este contenido
Summary
ONVO's promise of creating "3d bio-printed organs" for humans is a pipe dream decades away, and ONVO has neither the capital nor people necessary to succeed at such a venture.
ONVO's 3D bioprinting technology is far too slow and expensive to deliver a viable product for drug toxicity testing, the only near-term market identified by management.
ONVO's patent protection is extremely weak and does not come close to claiming all of the methods necessary to "print" human organs in the future.
ONVO scientific co-founder, Gabor Forgacs, has left his role at the company and is pursuing more viable opportunities (synthetic leather & meat) with notable venture capital backers.
ONVO executives are cashing out: the top three (Keith Murphy, Barry Michaels and Sharon Presnell) have sold ~$7 million worth of ONVO stock and pay themselves nearly $1 million annually.
[Editor's Note: Some facts have been corrected in this article after we were contacted by Organovo's management]
I am writing this solely to demonstrate high quality trade ideas for my investment firm, Valkyrie Capital. In doing so, I am putting my personal fruta (and that of my firm) on the line. I am not a serial short seller and ONVO had originally been brought to me as a long idea, but after some research, it has become my top short idea for 2014. While I am short, I am not looking to deliberately "short and distort" either: my position is based on detailed research, my own deductions and an expectation that Organovo's share price will decline significantly before December 2014. It's also worth noting I do not post frequently and my last post recommended long positions in Two Harbors (TWO) LEAPs and levered Annaly Capital (NLY) preferred stock on December 16th, which are both up more than 50% and 18% - 25%, respectively.
Yo por artículos como este me acorazoné y acabé vendiendo perdiendo un 10% .Vaya rachita que llevo :ouch: